SUPN - ス―パ―ナス・ファ―マス―ティカルズ (Supernus Pharmaceuticals Inc.)

SUPNのニュース

   $146.74 Million in Sales Expected for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) This Quarter  2021/12/24 01:54:42 Dakota Financial News
Equities analysts expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to post sales of $146.74 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Supernus Pharmaceuticals earnings. The lowest sales estimate is $141.50 million and the highest is $150.04 million. Supernus Pharmaceuticals posted sales of $143.56 million during the same quarter []
   Ziegler Capital Management LLC Purchases 9,362 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)  2021/12/18 11:16:47 Transcript Daily
Ziegler Capital Management LLC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 34.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,837 shares of the specialty pharmaceutical companys stock after acquiring an additional 9,362 shares during the quarter. Ziegler Capital Management LLC owned []
   Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Hold at Zacks Investment Research  2021/12/18 07:50:42 ETF Daily News
Zacks Investment Research cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several [] The post Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Hold at Zacks Investment Research appeared first on ETF Daily News .
   Virginia Retirement Systems ET AL Sells 5,500 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)  2021/12/14 09:48:47 Transcript Daily
Virginia Retirement Systems ET AL cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 19.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,300 shares of the specialty pharmaceutical companys stock after selling 5,500 shares during the quarter. Virginia Retirement Systems ET ALs []
   Analysts Expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Will Post Earnings of $0.20 Per Share  2021/12/14 08:08:41 Dakota Financial News
Brokerages expect that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will announce $0.20 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Supernus Pharmaceuticals earnings. The highest EPS estimate is $0.35 and the lowest is $0.12. Supernus Pharmaceuticals posted earnings per share of $0.57 in the same quarter last year, which []
   Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to Post FY2022 Earnings of $1.46 Per Share, Jefferies Financial Group Forecasts  2021/12/04 06:58:42 Dakota Financial News
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Equities researchers at Jefferies Financial Group lifted their FY2022 EPS estimates for Supernus Pharmaceuticals in a research note issued to investors on Wednesday, December 1st. Jefferies Financial Group analyst D. Steinberg now anticipates that the specialty pharmaceutical company will post earnings of $1.46 per share for the year, up from []
   Jefferies Financial Group Initiates Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)  2021/12/03 08:26:41 ETF Daily News
Equities researchers at Jefferies Financial Group started coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research note issued to investors on Wednesday, The Fly reports. The firm set a buy rating and a $44.00 price target on the specialty pharmaceutical companys stock. Jefferies Financial Groups price target would indicate a potential upside of 41.12% [] The post Jefferies Financial Group Initiates Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN) appeared first on ETF Daily News .
   Frontier Capital Management Co. LLC Has $15.44 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)  2021/12/02 13:34:42 Transcript Daily
Frontier Capital Management Co. LLC lowered its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 29.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 579,073 shares of the specialty pharmaceutical companys stock after selling 237,658 shares during the period. Frontier Capital Management []
   Mitsubishi UFJ Asset Management UK Ltd. Buys New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)  2021/11/30 15:52:42 Dakota Financial News
Mitsubishi UFJ Asset Management UK Ltd. acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 35,000 shares of the specialty pharmaceutical companys stock, valued at approximately $933,000. Mitsubishi UFJ Asset Management UK Ltd. owned []
   Biopharmaceutical firm Supernus Pharmaceuticals hit by Hive ransomware during an ongoing acquisition  2021/11/29 13:17:41 Security Affairs
Biopharmaceutical company Supernus Pharmaceuticals discloses a ransomware attack, the Hive ransomware claims to have stolen company data.
   Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to Post FY2022 Earnings of $1.46 Per Share, Jefferies Financial Group Forecasts  2021/12/04 06:58:42 Dakota Financial News
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Equities researchers at Jefferies Financial Group lifted their FY2022 EPS estimates for Supernus Pharmaceuticals in a research note issued to investors on Wednesday, December 1st. Jefferies Financial Group analyst D. Steinberg now anticipates that the specialty pharmaceutical company will post earnings of $1.46 per share for the year, up from []
   Jefferies Financial Group Initiates Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)  2021/12/03 08:26:41 ETF Daily News
Equities researchers at Jefferies Financial Group started coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research note issued to investors on Wednesday, The Fly reports. The firm set a buy rating and a $44.00 price target on the specialty pharmaceutical companys stock. Jefferies Financial Groups price target would indicate a potential upside of 41.12% [] The post Jefferies Financial Group Initiates Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN) appeared first on ETF Daily News .
   Frontier Capital Management Co. LLC Has $15.44 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)  2021/12/02 13:34:42 Transcript Daily
Frontier Capital Management Co. LLC lowered its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 29.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 579,073 shares of the specialty pharmaceutical companys stock after selling 237,658 shares during the period. Frontier Capital Management []
   Mitsubishi UFJ Asset Management UK Ltd. Buys New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)  2021/11/30 15:52:42 Dakota Financial News
Mitsubishi UFJ Asset Management UK Ltd. acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 35,000 shares of the specialty pharmaceutical companys stock, valued at approximately $933,000. Mitsubishi UFJ Asset Management UK Ltd. owned []
   Biopharmaceutical firm Supernus Pharmaceuticals hit by Hive ransomware during an ongoing acquisition  2021/11/29 13:17:41 Security Affairs
Biopharmaceutical company Supernus Pharmaceuticals discloses a ransomware attack, the Hive ransomware claims to have stolen company data.

calendar